login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MERSANA THERAPEUTICS INC (MRSN) Stock News
USA
- NASDAQ:MRSN -
US59045L2051
-
Common Stock
9.44
USD
-0.14 (-1.46%)
Last: 11/3/2025, 4:30:01 PM
9.44
USD
0 (0%)
After Hours:
11/3/2025, 4:30:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MRSN Latest News, Press Relases and Analysis
All
Press Releases
2 months ago - By: Zacks Investment Research
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
2 months ago - By: Zacks Investment Research
Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
3 months ago - By: Zacks Investment Research
- Mentions:
RNA
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: The Motley Fool
Mersana Misses Fiscal Q2 Revenue Target
3 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
3 months ago - By: Benzinga
A Look at Mersana Therapeutics's Upcoming Earnings Report
6 months ago - By: Benzinga
An Overview of Mersana Therapeutics's Earnings
3 months ago - By: Zacks Investment Research
- Mentions:
STOK
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
VTGN
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
3 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
3 months ago - By: Zacks Investment Research
- Mentions:
RXRX
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split
5 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
6 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics to Present at Upcoming Investor Conferences
6 months ago - By: Mersana Therapeutics, Inc.
CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
6 months ago - By: Zacks Investment Research
- Mentions:
AFMD
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
6 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
6 months ago - By: Zacks Investment Research
- Mentions:
ABUS
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Zacks Investment Research
- Mentions:
IGMS
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
6 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
6 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
7 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
8 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
8 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics to Present at Upcoming Investor Conferences
8 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
9 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9 months ago - By: Mersana Therapeutics, Inc.
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
10 months ago - By: Yahoo Finance
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
Please enable JavaScript to continue using this application.